This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

VectivBio Holding Future Growth

Future criteria checks 2/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for VectivBio Holding.

Key information

16.8%

Earnings growth rate

24.8%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	62.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	23 Jun 2023

Recent future growth updates

Recent updates

VectivBio gains on pricing of $125M underwritten offering of ordinary shares

Oct 13

VectivBio Holding rallies after Piper Sandler initiates Bull rating on biopharma stock

Jul 01

Dosing underway in VectivBio's mid-stage apraglutide study in short bowel syndrome

Jun 15

Earnings and Revenue Growth Forecasts

NasdaqGS:VECT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	30	-161	N/A	N/A	2
12/31/2024	5	-139	N/A	N/A	2
12/31/2023	1	-121	N/A	N/A	2
12/31/2022	27	-94	-56	-56	N/A
9/30/2022	27	-83	N/A	N/A	N/A
6/30/2022	26	-72	-45	-45	N/A
3/31/2022	13	-80	-59	-59	N/A
12/31/2021	N/A	-87	-72	-72	N/A
9/30/2021	N/A	-87	N/A	N/A	N/A
6/30/2021	N/A	-87	N/A	N/A	N/A
3/31/2021	N/A	-74	N/A	N/A	N/A
12/31/2020	N/A	-60	-38	-38	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VECT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VECT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VECT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VECT's revenue (62.6% per year) is forecast to grow faster than the US market (7.4% per year).

High Growth Revenue: VECT's revenue (62.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VECT's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

VectivBio Holding Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 7.6% to US$20.80

Price target increased to US$23.80

Recent updates

Price target decreased by 7.6% to US$20.80

VectivBio Holding AG Announces the Resignation of Chahra Louafi from the Board of Directors

Vectivbio Holding AG Appoints Wouter Joustra as Member of the Board of Directors

VectivBio Holding AG Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure

Price target increased to US$23.80

VectivBio Holding AG Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients with Colon-In-Continuity

VectivBio gains on pricing of $125M underwritten offering of ordinary shares

High number of new directors

VectivBio Holding rallies after Piper Sandler initiates Bull rating on biopharma stock

VectivBio Holding AG announced that it has received $19.999995 million in funding from Forbion Capital Partners B.V.

VectivBio Holding AG announced that it expects to receive $19.999995 million in funding from Forbion Capital Partners B.V.

VectivBio Holding AG announced that it expects to receive $19.999995 million in funding from Forbion Capital Partners B.V.

VectivBio Holding AG Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-Versus-Host Disease

High number of new and inexperienced directors

VectivBio Holding AG Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications

VectivBio Holding AG, Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

VectivBio Holding AG (NasdaqGS:VECT) completed the acquisition of Comet Therapeutics, Inc.

VectivBio Holding AG (NasdaqGS:VECT) entered into a definitive agreement Comet Therapeutics, Inc from Canaan Management, Inc., Sofinnova Partners SAS, INKEF Netherlands Manager B.V. and Mission BioCapital.

VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease

VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients with Short Bowel Syndrome with Intestinal Failure

Dosing underway in VectivBio's mid-stage apraglutide study in short bowel syndrome

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies